Want to see ENSC full AI Analyst Report?
ENSC Stock Chart & Stats
$0.40
<$0.01(0.08%)
At close: 4:00 PM EDT
$0.40
<$0.01(0.08%)
Day’s Range― - ―
52-Week Range$0.23 - $2.26
Previous CloseN/A
Volume225.00K
Average Volume (3M)516.66K
Market Cap
$9.15M
Enterprise Value$2.97M
Total Cash (Recent Filing)$676.70K
Total Debt (Recent Filing)$196.84K
Price to Earnings (P/E)―
Beta2.46
Next Earnings
Nov 16, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding19,456,795
10 Day Avg. Volume763,661
30 Day Avg. Volume516,664
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue2.55
Enterprise Value/Gross Profit2.55
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$2.00Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$4.60M
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionThe Cy Biopharma acquisition broadens Ensysce’s clinical pipeline beyond its opioid programs by adding CY-200, which has FDA Orphan Drug Designation for Complex Regional Pain Syndrome. This creates another differentiated development pathway and expands potential long-term opportunities in pain treatment.
Financing SupportThe initial Series C financing provides substantial capital to support the combined company after the Cy Biopharma transaction. Although additional funding depends on a clinical milestone, the proceeds can extend development activities and reduce immediate pressure to fund programs solely through repeated financings.
Proprietary Drug TechnologiesEnsysce’s proprietary technologies target abuse, overdose, and adverse-event risks associated with opioid analgesics. Addressing these persistent safety concerns gives the company a focused product strategy and could support differentiation if its clinical-stage candidates demonstrate the intended protection and pain-management benefits.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow shows that Ensysce is consuming capital to fund operations rather than generating cash internally. Continued burn increases dependence on financing or collaboration proceeds, and can constrain the pace of development if external funding becomes less available.
Limited Commercial RevenueRevenue remains very small relative to the company’s losses, reflecting a clinical-stage business without meaningful commercial product scale. This limits operating leverage and leaves future value dependent on successful development, regulatory progress, and eventual partnerships or product commercialization.
Nasdaq Listing RiskThe company faces multiple ongoing Nasdaq requirements, including continued equity compliance, initial listing standards after the change of control, and restoration of the minimum bid price. Failure to satisfy these conditions could disrupt trading access and complicate financing, governance, and investor participation.
Ensysce Biosciences News
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $0.23 and its highest was $2.25 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $9.15M.
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 22 days.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on Aug 19, 2026. The company reported -$0.2 earnings per share for the quarter.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Undervalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate is -0.12.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 19,456,795 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$0.2 in its last earnings report. Following the earnings report the stock price went up 0.779%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ensysce Biosciences
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
ENSC Stock 12 Month Forecast
Average Price Target
$2.00
▲(400.00% Upside)
Technical Analysis
Ownership Overview
4.71% Insiders
0.17% Mutual Funds
0.02% Other Institutional Investors
95.03% Public Companies and
Individual Investors